NASDAQ:GILD
Gilead Stock News
$73.01
+0.600 (+0.83%)
At Close: Mar 27, 2024
Gilead strikes deal to acquire CymaBay for $4.3 billion
08:42am, Monday, 12'th Feb 2024
Gilead Sciences Inc. GILD, -0.18% said Monday it has reached a deal to acquire CymaBay Therapeutics Inc. CBAY, +2.92% for $32.50 per share in cash, a 27% premium to CymaBay's closing price Friday, for
7 Biotech Stocks Fighting America's Deadliest Diseases
04:10pm, Thursday, 08'th Feb 2024
Unlike many other market segments, biotech stocks stand out for their direct relevance. For example, investors who typically wager on aerospace and defense plays usually aren't fighter pilots.
Gilead-backed Kyverna Therapeutics valued at $1.4 bln in stellar debut
01:43pm, Thursday, 08'th Feb 2024
Shares of Kyverna Therapeutics jumped 55.7% in their market debut on Thursday, giving the biopharmaceutical company that is backed by Gilead Sciences a market capitalization of $1.4 billion.
Why Gilead Sciences Stock Dropped Today
03:48pm, Wednesday, 07'th Feb 2024
Gilead delivered a mixed fourth quarter relative to expectations. The biopharma giant also issued underwhelming forward guidance.
Daily Dividend Report: Mastercard, MMM, Gilead, Keurig, Zoetis
03:36pm, Wednesday, 07'th Feb 2024
Mastercard today announced that its Board of Directors has declared a quarterly cash dividend of 66 cents per share. The cash dividend will be paid on May 9, 2024 to holders of record of its Class A c
Gilead (GILD) Q4 Earnings Miss Estimates, Sales Top on Veklury
03:01pm, Wednesday, 07'th Feb 2024
Gilead (GILD) posts mixed results for the fourth quarter. Sales beat estimates on the better-than-expected performance of Veklury due to higher hospitalizations at the end of 2023.
Brian Belski makes big trades on Snap, Chesapeake Energy, DoorDash, Gilead, and UnitedHealth
01:28pm, Wednesday, 07'th Feb 2024
Brian Belski, chief investment strategist at BMO Capital Markets, joins 'Halftime Report' to break down his latest trades.
Gilead Sciences, Inc. (GILD) Q4 2023 Earnings Call Transcript
08:24pm, Tuesday, 06'th Feb 2024
Gilead Sciences, Inc. (GILD) Q4 2023 Earnings Call Transcript
Gilead (GILD) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
07:31pm, Tuesday, 06'th Feb 2024
The headline numbers for Gilead (GILD) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estima
Late-Session Earnings Bonanza: Ford, Chipotle, Snap & More
07:05pm, Tuesday, 06'th Feb 2024
Markets bounced back this Tuesday from a Monday sell-off, though not all the way back to Friday highs.
Gilead Rode An Unexpected Source For Its Sales Beat, But Profit Came Up Short
04:17pm, Tuesday, 06'th Feb 2024
Gilead came up with a mixed fourth quarter late Tuesday as sales of its Covid treatment bolstered sales. GILD stock slipped in late trades.
Gilead quarterly revenue drops 4%, oral COVID drug fails trial
04:06pm, Tuesday, 06'th Feb 2024
Gilead Sciences on Tuesday said its fourth-quarter revenue dipped 4% on lower sales of HIV drugs and Veklury, an infused drug for hospitalized COVID-19 patients, while its adjusted profit rose 3% due
Earnings, Fed Speakers Dominate Activity; Lilly Beats, Spotify Misses
11:46am, Tuesday, 06'th Feb 2024
Investors of Lilly (LLY) are responding to the eye-opening efficacy of obesity drugs Mounjaro and Zepbound.
Gilead (GILD) Gears Up to Report Q4 Earnings: Whats in Store?
09:31am, Friday, 02'nd Feb 2024
Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports its fourth-quarter 2023 results.
3 Top Pharma Stocks to Buy Now: February 2024
05:00pm, Thursday, 01'st Feb 2024
Looking for pharma stocks to buy in February 2024? The pharmaceutical industry has always drawn a big crowd of investors.